Sizavaleucel is under clinical development by Medeor Therapeutics and currently in Phase III for Kidney Transplant Rejection. According to GlobalData, Phase III drugs for Kidney Transplant Rejection have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sizavaleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sizavaleucel overview

MDR-101 is under development for the treatment of kidney transplant rejection with HLA-Matched Living Donor Kidney Transplant (LDKT). The drug candidate comprises organ donor-derived CD34+ hematopoietic stem and progenitor cells and CD3+ T cells. MDR-101 is administered as an intravenous infusion. The drug candidate is developed based on MDR-10X technology.

Medeor Therapeutics overview

Medeor Therapeutics is a biotechnology company that discover and develops cellular immunotherapies to immune and hematological diseases. The company is headquartered in South San Francisco, California, the US.

For a complete picture of Sizavaleucel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.